TickerTalks
Browse all tickers →
TickerTalks›$NGEN
NGNGEN

NervGen Pharma Corp. Common stock

$NGEN·$134M·Biotechnology·Healthcare
$1.66+1.2%YTD-71.1%1Y-61.1%
Mentions · last 7 days
2026-07-29: 1 posts2026-07-30: 0 posts2026-07-31: 0 posts2026-08-01: 0 posts2026-08-02: 0 posts2026-08-03: 3 posts2026-08-04: 3 posts70%
Price updated 4h ago·X counts updated 3h ago
NGNGEN
$NGENNervGen Pharma Corp. Common stock
$1.66+1.22%7 posts0%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Today's AI verdict on what's driving $NGEN, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Too early to tellEvent coming upAI verdict · as of 2026-08-03

A known event soon (earnings, a ruling, etc.) will likely decide the next move.

NervGen Pharma is the NVG-291-nerve-injury clinical biotech down 72% YTD — Aug 21 Q2 print plus positive CONNECT SCI Phase 1b/2a biomechanical gait data plus $60M offering is the setup.

NervGen Pharma Corp. is a specific US-listed clinical-stage biotechnology franchise — NVG-291 for nerve injuries and progressive neurodegenerative diseases, deactivating natural biological mechanisms impeding nervous-system repair. Up 1% today, down 72% year to date, and down 62% over 12 months, sitting on an Aug-21-earnings-plus-Phase-1b/2a tape.

Where it stands:

  • The business is pre-revenue: reported quarters at $0 revenue with EPS -$0.13, -$0.06, -$0.44, -$0.02 — pure clinical-stage cash-burn.
  • The valuation is speculative: TTM P/E of -8.4 (loss-making), forward analyst estimates model FY26 EPS -$0.24 improving to FY29 $0.33 with $127M revenue (n=1-3 analysts) — the multi-year commercialization pathway is the whole thesis.
  • The specific positive catalyst is dated and named: NervGen Announces Positive Independent Blinded Biomechanical Gait Analyses Demonstrating Genuine Neural Recovery with NVG-291 in Phase 1b/2a CONNECT SCI Study 5/26 — a specific pattern where the Phase 1b/2a CONNECT SCI data supports the mechanism thesis.
  • The strategic tape is a specific dilutive-plus-catalyst signal: NervGen Announces Pricing of US$60.0 Million Public Offering of Securities 5/21 — the specific pattern where the $60M raise strengthens the runway before the Aug 21 print.
  • The framing signal is specific: NervGen Pharma I Think The Biggest Risks Are Now Behind It (Seeking Alpha 7/2).

Aug 21 Q2 earnings needs continued NVG-291 Phase 1b/2a-plus-CONNECT SCI data plus dated commentary on the $60M runway deployment and neurological-plus-neurodegenerative pathway to trigger the event-ahead tape; a specific NVG-291 clinical walk-back or a further dilutive raise would take the stock back toward the 52-week low.

What to watch: Aug 21 Q2 earnings — good = continued NVG-291 Phase 1b/2a-plus-CONNECT SCI data with dated commentary on the $60M runway deployment and neurological-plus-neurodegenerative pathway; bad = a specific NVG-291 clinical walk-back or a further dilutive raise, which takes the stock back toward the 52-week low.

On the calendar: 2026-08-21 — Q2 earnings

Read the AI verdict + X sentiment for $NGEN

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Clinical-stage biotech blocking CSPG inhibitory signaling to enable nerve regeneration after spinal cord injury.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $NGEN.

Biotechnology · Healthcare

No material change from last week — ADA conference oral formulation competition is bifurcating biotech multiples between GLP-1 platform holders and precision oncology innovators.

What this means for $NGEN

Neutral — Clinical-stage biotech blocking CSPG inhibitory signaling to enable nerve regeneration after spinal cord injury; limited read-through from biotechnology macro dynamics to this specific revenue mix.

Top industry ETF

$IBBiShares Biotechnology ETF
+12.1%YTD
+40.5%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-8.4How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-7.2%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
0.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-4.8%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
0.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-175%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
0.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q1 2026May 18, 2026$-0.01$-0.07+80.4%
Q4 2025Mar 31, 2026$-0.26$-0.06-304.6%
Next earningsFri, Aug 21·consensus EPS $-0.09

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$0———$-0.02$-8.3M
Q4 FY25$0———$-0.44$-10.1M
Q3 FY25$0———$-0.06$-5.3M
Q2 FY25$0———$-0.13$-3.7M

Forward consensus

5-year forecast · up to 2 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$0$0 – $0-$0.24-$0.26 – -$0.210
FY27$0$0 – $0-$0.30-$0.61 – $0.000
FY28$6.4M$1.5M – $11.4M-$0.22-$0.44 – -$0.002
FY29$126.6M$28.8M – $224.4M$0.33-$0.00 – $0.671
FY30$319.1M$72.6M – $565.7M$1.40-$0.01 – $2.811

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.3×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.—Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-14.7%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.—Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMid float · 64.4M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.4% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.695-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

No material 8-K / SC 13D / S-3 / 424B5 filings in the last 180 days.

+ 19 other (10 6-Ks · 4 SUPPLs · 1 EFFECT · 1 F-X) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

NervGen Pharma: I Think The Biggest Risks Are Now Behind Itseekingalpha.com·34d agoNervGen Announces Positive Independent, Blinded Biomechanical Gait Analyses Demonstrating Genuine Neural Recovery with NVG-291 in Phase 1b/2a CONNECT SCI Studyglobenewswire.com·71d agoNervGen Announces Pricing of US$60.0 Million Public Offering of Securitiesglobenewswire.com·75d agoNervGen Announces Pricing of US$60.0 Million Public Offering of Securitiesglobenewswire.com·75d agoNervGen Announces Proposed Public Offering of Securitiesglobenewswire.com·75d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$REPL$REGN$IBRX$CAPR$HALO$AURA$ABCL$MRNA
Voices on X · last 7 days

No standout posts about $NGEN on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport